Fusion Antibodies (FAB) Competitors GBX 8.50 -0.52 (-5.76%) As of 11:50 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock FAB vs. OKYO, TRX, SAR, AOR, AREC, POLB, RLM, NSCI, OPTI, and IXIShould you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include OKYO Pharma (OKYO), Tissue Regenix Group (TRX), Sareum (SAR), AorTech International (AOR), Arecor Therapeutics (AREC), Poolbeg Pharma (POLB), Realm Therapeutics (RLM), NetScientific (NSCI), OptiBiotix Health (OPTI), and IXICO (IXI). These companies are all part of the "biotechnology" industry. Fusion Antibodies vs. Its Competitors OKYO Pharma Tissue Regenix Group Sareum AorTech International Arecor Therapeutics Poolbeg Pharma Realm Therapeutics NetScientific OptiBiotix Health IXICO OKYO Pharma (LON:OKYO) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends. Which has better valuation & earnings, OKYO or FAB? Fusion Antibodies has higher revenue and earnings than OKYO Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-£6.70M-£0.01N/AFusion Antibodies£2.09M3.82-£4.10M-£4.45-1.91 Which has more risk & volatility, OKYO or FAB? OKYO Pharma has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, Fusion Antibodies has a beta of 0.49, suggesting that its stock price is 51% less volatile than the S&P 500. Do institutionals & insiders believe in OKYO or FAB? 21.0% of Fusion Antibodies shares are held by institutional investors. 31.9% of OKYO Pharma shares are held by insiders. Comparatively, 11.4% of Fusion Antibodies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor OKYO or FAB? In the previous week, OKYO Pharma's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score. Company Overall Sentiment OKYO Pharma Neutral Fusion Antibodies Neutral Is OKYO or FAB more profitable? OKYO Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Fusion Antibodies' return on equity of -137.11% beat OKYO Pharma's return on equity.Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A -397.13% -154.72% Fusion Antibodies -195.95%-137.11%-63.78% SummaryFusion Antibodies beats OKYO Pharma on 7 of the 10 factors compared between the two stocks. Get Fusion Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FAB vs. The Competition Export to ExcelMetricFusion AntibodiesBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£8.00M£136.73M£5.71B£3.02BDividend YieldN/A3.74%4.60%5.02%P/E Ratio-1.913.7428.07160.81Price / Sales3.824,472.07459.47278,114.25Price / Cash9.0213.1936.5527.97Price / Book2.4242.318.614.69Net Income-£4.10M-£90.99M£3.24B£5.90B7 Day Performance3.79%4.91%3.83%0.28%1 Month Performance32.85%8.83%10.40%8.61%1 Year Performance142.86%188.67%34.13%78.50% Fusion Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FABFusion AntibodiesN/AGBX 8.50-5.8%N/A+159.2%£8.00M£2.09M-1.9148OKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownTRXTissue Regenix GroupN/AGBX 25-3.8%N/A-42.4%£22.54M£31.98M-25.81120Gap DownSARSareumN/AGBX 18flatN/A-41.1%£22.49MN/A-4.263,211AORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383ARECArecor TherapeuticsN/AGBX 49flatN/A-40.5%£18.50M£6.04M-1.7310High Trading VolumePOLBPoolbeg PharmaN/AGBX 3-4.8%N/A-77.8%£15.42MN/A0.0012Gap DownRLMRealm TherapeuticsN/AN/AN/AN/A£13.41M£501.92K-0.66N/ANSCINetScientificN/AN/AN/AN/A£12.81M£1.45M-486.3626OPTIOptiBiotix HealthN/AGBX 11.01-8.3%N/A-62.9%£10.78M£590.01K-3.491IXIIXICON/AGBX 11+12.8%N/A+74.8%£10.19M£11.50M-2.8589Negative NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies OKYO Pharma Alternatives Tissue Regenix Group Alternatives Sareum Alternatives AorTech International Alternatives Arecor Therapeutics Alternatives Poolbeg Pharma Alternatives Realm Therapeutics Alternatives NetScientific Alternatives OptiBiotix Health Alternatives IXICO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:FAB) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
